1201593-65-8

Usage

Uses

Used in Pharmaceutical Industry:
(S)-2-aMino-3-cyclobutylpropanoic acid is used as a therapeutic agent for treating pain, inflammation, and neurological disorders due to its inhibitory effect on the enzyme N-acylethanolamine acid amidase (NAAA). This inhibition can modulate the endocannabinoid system, which plays a crucial role in various physiological processes, including pain perception and neuroprotection.
Used in Drug Development:
(S)-2-aMino-3-cyclobutylpropanoic acid is used as a lead compound in the development of new medications targeting the endocannabinoid system. Its chiral nature and biological activity make it a valuable candidate for designing enantiomer-specific drugs with improved efficacy and reduced side effects.
Used in Preclinical Research:
(S)-2-aMino-3-cyclobutylpropanoic acid is used as a research tool in preclinical studies to investigate the role of the endocannabinoid system in various diseases and conditions. Its ability to modulate this system provides insights into potential therapeutic targets and mechanisms of action for the development of novel treatments.

Upstream product

• 17247-58-4 (Bromomethyl)cyclobutane 
• 1068-90-2 2-acetylaminomalonic acid diethyl ester 
• 75-56-9 methyloxirane 
• 16408-62-1 cyclobutylmethyl iodide 
• 63659-30-3 cyclobutylmethyl methanesulfonate 
• 4415-82-1 cyclobutanemethanol 
• 13295-53-9 cyclobutylmethyl 4-methylbenzenesulfonate 

Relevant academic research and scientific papers

Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-((S)-3-(Cyclopent-1-en-1-yl)-1-((R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propenamide)

Selective immunoproteasome inhibition is a promising approach for treating autoimmune disorders, but optimal proteolytic active site subunit inhibition profiles remain unknown. We reveal here our design of peptide epoxyketone-based selective low molecular mass polypeptide-7 (LMP7) and multicatalytic endopeptidase complex subunit-1 (MECL-1) subunit inhibitors. Utilizing these and our previously disclosed low molecular mass polypeptide-2 (LMP2) inhibitor, we demonstrate a requirement of dual LMP7/LMP2 or LMP7/MECL-1 subunit inhibition profiles for potent cytokine expression inhibition and in vivo efficacy in an inflammatory disease model. These and additional findings toward optimized solubility led the design and selection of KZR-616 disclosed here and presently in clinical trials for treatment of rheumatic disease.

Substituted Pyrazinone Amides

The present invention provides compounds of Formula (I) that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by glucokinase. The variables R1, R2

Anticoagulant peptidyl-arginine aldehyde derivatives

The invention relates to new peptidyl-arginine aldehyde compounds of formula (I) Q-D-Xaa-Pro-Arg-H??(I) wherein Q represents an acyl group of formula Q′—OCO, wherein Q′ represents an alkyl-group with 1-3 carbon atoms, D-Xaa represents a 3-cyclobutyl-D-ala